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High-grade gliomasAbstract Introduction: Reliable early prediction response to therapy and time-to progression
(TTP) remains an important goal of High-grade glioma (HGG) research. Proton magnetic reso-
nance spectroscopy (H-MRS) has been applied with variable success in clinical application, and
we hypothesize that 1H-MRS in predictive value should perform well as a marker of TTP in
patients treated with concomitant chemoradiotherapy (CRT) after surgery
Methods: (1)H-MRS was performed before surgery on 25 patients who had undergone resection of
HGGs and fulﬁlled the inclusion criteria from 43 patients; then the ratios of lipid/creatine (Lip/Cr)
and myoinositol/creatine (mI/Cr) were determined in the solid tumor. CRT response was classiﬁed
as follows: complete resolution (CR), partial response (PR), stable disease (SD), and progressive
disease (PD) by comparison of pre-treatment and post-radiotherapy scans. TTP was deﬁned at
the time to radiographic progression by MacDonald criteria. Correlation was evaluated between
the ratios of Lip/Cr, mI/Cr and treatment response, TTP. The chi-square test and Pearson correla-
tion test were used for data analyses.
Results: Multivariate analysis revealed that the prognostic value of spectroscopic variables was
independent of age, sex, WHO histologic grade, extent of surgery, and Karnofsky score (KPS).
The correlation between the ratios of lipid/Cr and TTP was signiﬁcant (r= 0.894, P= 0.000),
886 L.M. sad, M. Hamisaand between the ratios of mI/Cr and TTP was also signiﬁcant (r= 0.891, P= 0.000). As predicted,
RT response correlated signiﬁcantly with TTP (r= 0.59, P= 0.002): median TTP was 49.9 days
for patients with PD compared with 202.7 days for SD, 208.0 days for PR, and 234.5 days for CR.
Conclusion: The ratios of Lip/Cr and mI/Cr of the solid tumor region before surgery could provide
important information in predicting CRT response and TTP in patients with HGGs treated by con-
current chemoradiation after surgery.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
The incidence of primary brain tumors has increased dramati-
cally over the past several decades. The term high grade gliomas
(HGG), is usually used to describe HO grade III and IV tumors.
Of these, glioblastomas account for 60–70%, anaplastic astrocy-
tomas for 10–15%, anaplastic oligodendrogliomas and anaplas-
tic oligoastrocytomas for about 10%, while anaplastic
ependymoma and anaplastic gangliogliomamake up the rest (1).
Despite aggressive treatment and research for over half a
century, survival for most patients is less than 18 months (2).
Radiotherapy (RT) remains the main adjuvant treatment
after surgical resection worldwide, despite signiﬁcant morbidity
including memory impairment, personality change and cogni-
tive decline in as much as two thirds of long-term survivors (3).
Trials of systemic chemotherapy provided mixed results but
overall were disappointing (4,5). However, the introduction of
temozolomide (TMZ) in the setting of newly-diagnosed GBM
and anaplastic astrocytoma has made a substantial impact in
the treatment of this disease (6,7).
Preliminary reports have shown that functional magnetic
resonance imaging (fMRI) techniques, such as diffusion
weighted imaging (DWI), perfusion weighted imaging (PWI),
and proton magnetic resonance spectroscopy (1H-MRS), yield
structural and metabolic information that may provide better
insight into tumor functionality and improve the prognostic
stratiﬁcation of HGG (8). Several studies have evaluated some
particular resonances of the spectrum and have found them to
be useful for predicting patient outcome in gliomas (9–11). Oh
et al. (12) found a signiﬁcantly shorter median survival time for
patients with a large volume of metabolic abnormality, mea-
sured by 1H-MRS. Majos et al. (13) demonstrated an inverse
correlation between resonance intensities in these regions at
both short echo time (STE) and patient survival (a high-inten-
sity value of the peaks of lipid (Lip) and myo-inositol (mI) cor-
relates with low survival), and a direct correlation between mI
and patient survival (a high-intensity value of the peak of mI
correlates with high survival). However, there are no reports
on the relation between the ratios of Lip/Cr or mI/Cr and
RT response, time-to-progression (TTP).
The purpose of this study was to determine which of the ra-
tios, Lip/Cr or mI/creatine (Cr), was the most relevant for pre-
dicting CRT response and TTP in HGG after surgery and to
analyze the potential of 1H-MRS for discriminating patients
with good or poor prognosis.
2. Patients and treatment
A total of 43 consecutive patients with HGG who underwent
1H-MRS between April 2012 and April 2013 were enrolled for
the study. In some of the patients, the spectrum was consideredto be of poor quality and these patients were excluded. Finally,
the deﬁnitive dataset of the study included 25 patients. A total of
25 patients with HGG, glioblastoma multiform (n= 19) and
anaplastic astrocytoma (n= 6), who underwent subtotal or to-
tal resection, were recruited to participate to test the efﬁcacy of
1H-MRS for the assessment of concurrent chemoradiotherapy
response. Patients with histologically conﬁrmed HGG who
had not received any prior therapy, and who had undergone
immediate postoperative computed tomography (CT) or MRI
within 24 h of surgery to assess the extent of resection were in-
cluded. All patients were treated with fractionated RT in daily
doses of 2 Gy to a total of 56–60 Gy with concurrent timodal
50mgm daily. Patients received timodal concurrent with radio-
therapy in dose of 100 mgm half an hour prior to radiotherapy.
They underwent 1H-MRS at the time ofMRI before concurrent
CRT. MRI was performed at follow-up to determine CRT re-
sponse 4 weeks after completion of the therapy. The patients
were subsequently assessed by their neuro-oncologist at 2-
month intervals according to the local standard of care (See
Case numbers 1 and 2).
2.1. Image acquisition
Data were acquired with a 1.5 T MR imaging scanner (GE –
high signa). Single-voxel 1H-MRS was performed as the last
sequence of the MR imaging examination. A volume of inter-
est (VOI) between 1.5 and 2.0 cm3 was placed for performing
1H-MRS in HGG. Speciﬁcally, the VOI location and size were
determined with the aim of positioning the largest possible
voxel within the solid brain mass, with minimal contamination
from the surrounding non-affected tissue or from non-enhanc-
ing areas of the tumor, when possible. One spectrum was ac-
quired from the VOI: STE (TR/TE, 1500/35) (Case 3).
A spectrum was considered to be of poor quality when large
peak line width, poor signal intensity-to-noise ratio, or obvious
artifacts precluded precise quantiﬁcation of some areas of the
spectrum.
2.2. Response assessment
Radiological assessment of response was carried out according
to the current World Health Organization (WHO) 2000 modi-
ﬁed MacDonald criteria change in maximal perpendicular tu-
mor diameters 3 months after the conclusion of a therapeutic
protocol as follows: (14–16) complete response (CR) is deﬁned
as complete disappearance of abnormal contrast enhancement
in a patient not on steroids at the time of MRI; partial response
(PR) refers to a >50% decrease in volume measure of enhanc-
ing abnormality onMRI performedmore than 4 weeks after the
end of therapy in a patient on a stable or decreased steroid doses;
MRI after surgery showed space occupying lesion 2x3x4cm, choline /NAA ratio=1.8; 
myoinostol /NAA ratio=1.8:the sum of two ratios =2.9:cholin/creatine 
ratio=3.2___showed marked regression of previously detected mass. 
MRI----Post concurrent chemoradiotherapy showed cystic lesion by complementary 
MRS
Choline /NAA ratio=2 ; myoinostol /NAA ratio=1.8:the sum of two ratios =3.8 ; 
choline/creatine ratio=1.2-------compatible with radiation necrosis
Case number 1 A 52-year-old man treated for a glioblastoma multiforme by standard fractionated RT (total dose, 60 Gy) with
concurrent chemotherapy(timodal) with no progression.
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enhancement or a change that does not meet PR or PD criteria
(<50%decrease or<25% increase) in a patient on stable or de-
creased steroid dose; and progressive disease (PD) refers to a
>25% increase in volume measure of enhancing abnormalityin a patient on a stable or increased steroid dose. Patients were
classiﬁed as responders (CR and PR) or non-responders (SD
or PD) by comparison of post-treatment images to the pre-con-
current chemoradiotherapy (baseline) MRI images (17). TTP
was deﬁned as the time from diagnosis to recurrence.
Post fractionated  radiotherapy with concomitant timodal ----MRI with MRS ---- 
choline/NAA=1.8 (more than 1.9 malignant tumor), myoinsoitol/NAA=1.1, the sum of 
two ratios=2.9, choline/creatine=3.2---- finding are constant with marked regression of 
previously detected. 
Follow up after 6 months from end of concomitant chemoradiotherapy ------------- 
choline/NAA=1.8 (more than 1.9 malignant tumor) , myoinsoitol/NAA=1.1, the sum of 
two ratios=2.9, choline/creatine=0.9---- finding are constant with radiation necrosis 
Case number 2 Male patient aged 42 years with anaplastic astrocytoma ——————— postoperative status ——MRI with MRS——
choline/NAAA= 2.9 (more than 1.9 malignant tumor), myoinositol/NAA = 0.2, the sum of two ratios = 3.1, choline/creatine = 2.5
—— ﬁnding are constant with residual/RECCURRENCE TUMOR.
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Prognostic variables evaluated were both clinical (age, sex,
WHO grade, Karnofsky score (KPS), and extent of surgery)and spectroscopic (the ratios of Lip/Cr, mI/Cr). The statistical
signiﬁcance of the differences in the ratios of Lip/Cr, mI/Cr be-
tween response groups was analyzed using c2 test. The correla-
tion of ratios of Lip/Cr, mI/Cr with TTP was evaluated by
Post fractionated radiotherapy with concomitant timodal ----MRI with MRS ---- 
choline/NAA=2.5 (more than 1.9 malignant tumor), myoinsoitol/NAA=1.1, the sum of 
two ratios=2.9, choline/creatine=3.2---- finding are constant with marked progression of 
previously detected. 
Figure A before treatment MRI with MRS ---- choline/NAAA=2.9 (more than 1.9 
malignant tumor), myoinsoitol/NAA=0.2, the sum of two ratios=3.1, 
choline/creatine=2.5---- finding are constient with residual /RECCURRENCE TUMOR 
Case 3 Representative STE spectra from PD group to RT. A 42-year-old man treated for an anaplastic astrocytoma by standard
fractionated RT (total dose, 60 Gy) with TTP of 64 days. The main signiﬁcant differences are seen in the Lip and mI region.
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sponse and median TTP was evaluated with log-rank tests.
Kaplan–Meier curves were constructed by deﬁning TTP as
the time from the initial surgical diagnosis to the time of tumor
progression. For all statistical tests, a P value less than 0.05
was considered to indicate statistical signiﬁcance.
3. Results
A total of 25 patients fulﬁlled the inclusion criteria and were
retained in the study. Multivariate analysis revealed that the
prognostic value of spectroscopic variables was independent
of age, sex, WHO histologic grade, extent of surgery, and
KPS (Table 1).The dataset of 25 patients included four groups, and the ra-
tios of Lip/Cr, mI/Cr, TTP and the correlation are shown in
Table 2.
The correlation between the ratios of lipid/Cr of each group
and TTP was signiﬁcant (r= 0.894, P= 0.000), and that be-
tween the ratios of mI/Cr of each group and TTP was also sig-
niﬁcant (r= 0.891, P= 0.000).
As expected, CRT response correlated signiﬁcantly with
TTP (r= 0.590, P= 0.002). The log-rank test and Kaplan–
Meier curves revealed that patients with PD had a shorter
median TTP (49.9 days) compared with those with CR
(234.5 days). TTP was also signiﬁcantly longer in the PR group
(208.0 days) and SD group (202.7 days) than the PD group,
but not quite as long as in the CR group. After concurrent
Table 1 Patient data and prognostic factors in 25 patients
with HGG.
Prognostic factors TTP (days)
Age
 <50 (n= 10) 183.40 (114.0–256.32)
 >50(n= 15) 143.27 (96.54–192.93)
Sex
 Male (n= 16) 171.69 (122.11–219.11)
 Female (n= 9) 137.33 (72.01–223.43)
WHO grade
 Anplastic astrocytoma (n= 6) 164.63 (115.05–217.20)
 Glioblastoma multiforme (n= 19) 144.67 (63.83–225.84)
Performance status
 0–1(n= 14) 174.59 (117.84–269.87)
 2 (n= 11) 134.56 (69.45–215.76)
Extent of surgery
 Partial resection (n= 19) 142.50 (85.75–193.73)
 Complete resection (n= 6) 164.63 (115.05–217.20)
890 L.M. sad, M. Hamisachemoradiotherapy case 1 showed radiation necrosis with
MRS. case 2 showed residual or recurrrence with MRs.MRS
in case 3 showed progressive disease.
4. Discussion
It is important to identify responsive patients with HGG who
can take advantage of intensive treatments and non-responsive
ones for whom conservative support treatment is a choice. His-
topathology remains the reference standard for prognostic
assessment, providing an insight into the morphologic cyto-
structure of the tumor (18). Nevertheless, histopathology has
its limitations in providing prognostic value, and additional
factors have been deﬁned for stratifying patients into diverse
prognostic groups. A recursive partitioning analysis under-
taken by the Radiation Therapy Oncology Group identiﬁed
four risk classes for glioblastoma based on patient age, KPS,
neurologic function, mental status, and extent of surgery
(19,20). These items provide a prognostic assessment based
on factors related to patient status and effectiveness of the sur-
gical approach. Nevertheless, several researchers suggested
that there might be some metabolic information in tumors thatTable 2 Results of Lip/Cr and mI/Cr in each group, and the corre
Groups NI (mean) TTP
Responsive
 CR (n= 4) Lip/Cr = 0.327 234.
 PR (n= 3) Lip/Cr = 0.351 225.
Non responsive group
 SD (n= 10) Lip/Cr = 0.4187 197.
 DP(n= 8) Lip/Cr = 0.434 49.8
Responsive group
 CR(n= 4) mI/Cr = 0.123 234.
 PR(n= 3) mI/Cr = 0.096 225.
Non responsive group
 SD(n=) mI/Cr = 0.085 197.
 DP(n=) mI/Cr = 0.073 49.8
Signiﬁcant differences were found between groups.could help in specifying the prognosis of HGG and that this
information could be assessed in a non-invasive way by 1H-
MRS (14,20).
Our study has shown that the information provided by 1H-
MRS may be of help in the prognostic assessment of patients,
and we found two regions of the spectrum that have prognostic
value. The regions corresponding to lipids and mI, and these
spectroscopy points offer the opportunity to formulate ratios
between metabolites at STE to be used in a clinical setting.
Using ratios would have the advantage of producing a straight
forward quantitative assessment of the spectrum that would
not require any additional normalization procedure.
Our study demonstrates that there is an inverse correlation
between ratios of lipid/Cr at STE and patient TTP, and fur-
thermore, a direct correlation between ratios of mI/Cr at
STE and patient TTP.
Prior studies showed some prognostic value of the major
resonances of the spectrum, such as choline-containing com-
pounds, N-acetylaspartate, creatine, lipids, and lactate
(11,12). The methodology used in our study provided the
opportunity to detect differences in the area around mI, not
evaluated in previous studies.
Limitations of our study include the limited number of pa-
tients, and more data should be acquired. Since 1H-MRS can
be readily performed on most modern scanners in a short time,
without added risk or use of contrast, this could be of signiﬁ-
cant beneﬁt in monitoring patients who are responding well
and selecting patients who are not responding well to receive
additional chemotherapy or supplementary stereotactic
radiation.
In our study, we tried to deﬁne the relevant value of 1H-
MRS in HGG patients only with surgery and CRT for a prog-
nostic assessment. We found that the ratios of Lip/Cr, mI/Cr
at STE provided relevant prognostic information, and may of-
fer an early marker of treatment response. This predictive va-
lue of 1H-MRS concerning TTP could be very useful for
evaluating whether intensive oncologic therapy is necessary
in some patients.Conﬂict of interest
No potential conﬂicts of intersets were disclosed.lation among Lip/Cr, mI/Cr and TTP.
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